STAT+: FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy
Image Credit: STAT News

STAT+: FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy

Watchdoq July 11, 2025
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.

Read Full Article